Back to Search
Start Over
Physiological expression of PI3K H1047R mutation reveals its anti-metastatic potential in ErbB2-driven breast cancer
- Source :
- Oncogene. 41(25)
- Publication Year :
- 2021
-
Abstract
- p110α is a catalytic subunit of phosphoinositide 3-kinase (PI3K), a major downstream effector of receptor tyrosine kinase ErbB2, that is amplified and overexpressed in 20-30% of breast cancers, 40% of which have an activating mutation in p110α. Despite the high frequency of PIK3CA gain-of-function mutations, their prognostic value is controversial. Here, we employ a knock-in transgenic strategy to restrict the expression of an activated form of ErbB2 and p110α kinase domain mutation (p110α
Details
- ISSN :
- 14765594
- Volume :
- 41
- Issue :
- 25
- Database :
- OpenAIRE
- Journal :
- Oncogene
- Accession number :
- edsair.pmid..........ee8903cc1dabd310d56b73ae48cf789f